360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Exenatide

Type: Product

Name: Exenatide

First reported Jun 19 2013 - Updated 12 hours ago - 1 reports

AstraZeneca PLC

AstraZeneca and Bristol-Myers Squibb to Spotlight New Data at American Diabetes Association 73rd Scientific Sessions

AstraZeneca and Bristol-Myers Squibb Company announced that 33 abstracts on the companies' research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association (ADA) in Chicago, June 21-25.According ... [Published Individual.com - Jun 19 2013]

Entities: Bristol-Myers Squibb Company, AstraZeneca PLC, American Diabetes Association, Dapagliflozin

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Albany Medical College

Data from Albany Medical College Advance Knowledge in Peptide Research

(NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Current study results on Peptide Research have been published. According to news reporting out of Albany, New York, by NewsRx editors, research stated, "The effects of oral delivery ... [Published NewsRX - Jun 17 2013]

Entities: Albany Medical College, Peptide, Pramlintide, Exenatide

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Diabetes drugs may be linked to pancreatic cancer

A British Medical Journal (BMJ) investigation into two classes of type 2 diabetes drugs has prompted headlines in the Daily Mail.The newspaper claims, “Diabetes drugs taken by thousands linked to cancer of the pancreas and other serious health problems,” going ... [Published Nursing Times - Jun 17 2013]

Entities: Drugs, Pancreas, Pancreatic Cancer, pancreatitis

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Bristol-Myers Squibb Company

Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions

AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data ... [Published Yahoo! Finance - Jun 14 2013]

Entities: Bristol-Myers Squibb Company, AstraZeneca PLC, Dapagliflozin

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®

AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions® of the American Diabetes Association (ADA) ... [Published OSIX News - Jun 14 2013]

Entities: BYDUREON, Exenatide, Patient

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies

/PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of incretin-based diabetes ... [Published TickerTech.com - Jun 13 2013]

Entities: Intarcia Therapeutics Inc, Exenatide, GLP-1, Independent Review

First reported Jun 10 2013 - Updated Jun 11 2013 - 4 reports

New generation of diabetes drugs raising more concerns

CCFlickrsean dreilingerIn February researchers at Johns Hopkins University reported that people who took two GLP1 drugs sitagliptin Januvia and exenatide Byetta were twice as likely to be admitted to the hospital for acute pancreatitis than people taking ... [Published BioPortfolio - Jun 11 2013]

Entities: Diabetes, Drugs, sitagliptin, Exenatide

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Lixisenatide non-inferior to exenatide for diabetes

In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according to a study published online May 22 in Diabetes Care ... [Published Medical Xpress - Jun 07 2013]

Entities: Lixisenatide, Exenatide, Diabetes, Glycated Hemoglobin, Metformin

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Single-Blind Trial: Diabetes Drug Helps Parkinson’s, Maybe

Could an approved diabetes medication treat Parkinson’s disease? Perhaps, according to results published online May 20 in the Journal of Clinical Investigation. Scientists led by Thomas Foltynie, University College London, U.K., report that in a Phase ... [Published Alzheimer Research Forum - Jun 03 2013]

Entities: Exenatide, GLP-1, Placebo

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Physiological mechanisms for the increase in renal solute‐free water clearance by a glucagon‐like peptide‐1 mimetic

The aim of the present study was to clarify the mechanisms mediating the effect of a glucagon‐like peptide‐1 (GLP‐1) mimetic on solute‐free water excretion in rats.GLP‐1 mimetic (exenatide, 0.05–5.0 nmol/kg, i.m.) alone and with a V2‐antagonist (15 nmol/kg, ... [Published Bionity.com - May 30 2013]

Entities: Exenatide, glucagon, collecting duct, Peptide

First reported May 23 2013 - Updated May 24 2013 - 2 reports

Diabetes drug could slow down Parkinson's disease

A drug used to treat people with diabetes could help to slow down Parkinson's disease, a trial has found.Exenatide is currently taken by around six million diabetics in the UK because it controls glucose levels.However, trials carried out by a research ... [Published Barchester - May 24 2013]

Entities: Exenatide, Parkinson's Disease, Diabetes, Drugs

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Bydureon, exenatide, Revision: 1, Authorised

[Published Pending EC decisions and European Public Assess ... - May 21 2013]

Entities: Exenatide, BYDUREON

Quotes

In the report, Bank of America commented that, "We lowered our 2018 peak US Bydureon sales estimate to $730mn from $1.2bn due to slower TRx growth trends (see Charts 1 and 2) and potential upcoming competition from new entrants. We expect to see continued steady decline in total exenatide franchise share to Novo's Victoza, with Byetta losses more than offsetting Bydureon gains (ALKS receives 8% royalties on worldwide Bydureon sales). Our NPV estimate for Bydureon decreased from $5/sh to $3/sh, which lowered our PO to $27 ($29 prev.). Our Underperform rating is unchanged."

UPDATE: Bank of America Lowers PO on Alkermes on Reduced Bydureon Forecast [Published Benzinga.com - 19 hours ago]

...compound dapagliflozin," said John Yee, MD, MPH, vice president, head of Medical Affairs, AstraZeneca/Bristol-Myers Squibb U S Diabetes Alliance. "The diversity of data reflects our joint commitment to researching and delivering innovative medicines and treatment options to help patients overcome the burdens of diabetes."

AstraZeneca and Bristol-Myers Squibb to Spotlight New Data at American Diabetes Association 73rd ... [Published Individual.com - Jun 19 2013]

...According to news reporting out of Albany, New York, by NewsRx editors, research stated, "The effects of oral delivery of exenatide or pramlintide acetate in dodecyl maltoside (DDM) on energy balance and glycemic control in insulin-resistant obese db/db mice are enhanced when given in combination with [D-Leu-4]-OB3. To examine the anti-hyperglycemic influence of [D-Leu-4]-OB3 in a non-obese insulin-deficient animal model, we compared the effects of metformin (200mg/kg) and [D-Leu-4]-OB3 (40mg/kg) on energy balance and glycemic control... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."

Data from Albany Medical College Advance Knowledge in Peptide Research [Published NewsRX - Jun 17 2013]

...week for the BritishBritish Medical Journal (BMJ) on the safety of incretin-based therapies, the journal's editor Dr Fiona Godlee commented that "instead of engaging in open debate about legitimate and important scientific questions, the manufacturers have been unwilling to share their data [and] patients and doctors have not been kept properly informed about the uncertainties surrounding these drugs."

US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]

More Content

sort by: Date \| Relevance
Alkermes Rating Reiterated by Bank of America (... [Published Mideast Time - 18 hours ago]
UPDATE: Bank of America Lowers PO on Alkermes o... [Published Benzinga.com - 19 hours ago]
AstraZeneca and Bristol-Myers Squibb to Spotlig... [Published Individual.com - Jun 19 2013]
Data from Albany Medical College Advance Knowle... [Published NewsRX - Jun 17 2013]
ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #4... [Published Diabetes in Control - Jun 17 2013]
AstraZeneca and NGM form diabetes/ obesity part... [Published PMLive - Jun 17 2013]
Diabetes drugs may be linked to pancreatic cancer [Published Nursing Times - Jun 17 2013]
Bristol-Myers, AstraZeneca to present 33 abstra... [Published Yahoo! Finance - Jun 14 2013]
AstraZeneca and Bristol-Myers Squibb to Present... [Published OSIX News - Jun 14 2013]
US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]
Lilly to Present Late-Stage Pipeline Molecules ... [Published Individual.com - Jun 14 2013]
Intarcia Supports American Diabetes Association... [Published TickerTech.com - Jun 13 2013]
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013]
More Risks Shown for Oral Diabetes Drugs [Published PCRM - Jun 11 2013]
Statement on GLP-1 medicines used to treat diab... [Published MHRA - Jun 11 2013]
Has pancreatic damage from glucagon suppressing... [Published PharmaGossip - Jun 11 2013]
New generation of diabetes drugs raising more c... [Published BioPortfolio - Jun 11 2013]
Drugmakers in dock over diabetes therapies safe... [Published Pharma Times - Jun 11 2013]
Diabetes drugs may be linked to pancreatic cancer [Published Winsford Guardian - Jun 10 2013]
New generation of diabetes drugs raising more c... [Published MinnPost - Jun 10 2013]
Oramed Pharmaceuticals to Present at IATI-BioMe... [Published Barchart - Jun 10 2013]
Data on diabetes drug links to cancer withheld ... [Published PMLive - Jun 10 2013]
Diabetes drugs taken by thousands linked to can... [Published Mail Online UK - Jun 10 2013]
Oramed Pharmaceuticals Awarded Government Grant... [Published Pharmacy Choice - Jun 09 2013]
Office of the Chief Scientist Israel awards gra... [Published Pharmaceutical Business Review - Jun 08 2013]
22nd Annual Report: Top 100 Biotechnology Compa... [Published Pharma Live - Jun 07 2013]
Lixisenatide non-inferior to exenatide for diab... [Published Medical Xpress - Jun 07 2013]
Pennine Acute Trust top of the tree in diabetes... [Published Rochdale Online - Jun 06 2013]
ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #3... [Published Diabetes in Control - Jun 04 2013]
Protagonist Pulls in $14M, Led by J&J, For Pept... [Published Xconomy - Jun 04 2013]

Blogs

sort by: Date \| Relevance
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013] Diabetes Doctors And Drug Safety Watchdog Group Express More Concern Than Ever Following June 2013 BMJ Medical Journal Article (Posted by Tom Lamb at DrugInjuryWatch.com ) In mid-March 2013 we wrote this article, "Emerging Drug Safety Issue: ...
Has pancreatic damage from glucagon suppressing... [Published PharmaGossip - Jun 11 2013] BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3680 (Published 10 June 2013)Cite this as: BMJ 2013;346:f3680 Article Related content Article metrics Deborah Cohen, investigations editorAuthor Affiliations dcohen@bmj.com Incretin mimetics have been ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - May 21 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Mar 25 2013]
Emerging Drug Safety Issue: Possible Increased ... [Published Drug Injury Watch - Mar 18 2013] As "Pancreatitis Is On The Pathway Toward Pancreatic Cancer", Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com ) We last wrote about ...

Press Releases

sort by: Date \| Relevance
Bristol-Myers Squibb och AstraZeneca tar över ... [Published GlobeNewswire: Acquisitions News - Apr 01 2013]
Intarcia Enrolls First Patients in "FREEDOM" Gl... [Published PR Newswire: Health - Mar 21 2013]
Paid Diabetes Clinical Trial Now Enrolling at A... [Published PR.com Press Releases - Jan 29 2013]